C7orf50 Inhibitors

C7orf50 inhibitors encompass a wide array of compounds designed to affect diverse cellular pathways. Given the unspecified function of C7orf50, these inhibitors were chosen for their broad activity against conventional pathways. For instance, kinase inhibitors such as Staurosporine, LY294002, and Wortmannin target enzymatic activities crucial for cell signaling. The selection also includes inhibitors like U0126, SP600125, and PD98059, which are particularly notable for their capacity to regulate the MAPK/ERK pathway-a major determinant in cellular proliferation, differentiation, and survival.

Another layer of this chemical class consists of compounds such as Rapamycin, MG-132, Chloroquine, 2-Deoxy-D-glucose, Brefeldin A, and Epoxomicin. These molecules vary significantly in their targets, from cellular growth and autophagy (Rapamycin) to glycolysis (2-Deoxy-D-glucose). Brefeldin A's influence on protein transport provides a unique mechanism, while proteasome inhibitors like MG-132 and Epoxomicin alter the proteostasis within cells.